New modelling research, published in The Lancet Global Health journal, estimates that it could cost low- and middle-income countries around $52 billion over four weeks to provide an effective healthcare response to Covid-19.
That’s around $8.60 per person, assuming each country’s rate of spread remains unchanged.
- Discovery of four COVID-19 risk groups helps guide treatment
- COVID-19: Delta reopens cinemas, hotel restaurants
However, the sizeable costs of a COVID-19 response in the health sector are likely to escalate if transmission increases–rising to as much as US$62 billion over four weeks under a scenario where current restrictions are relaxed and transmission increases by 50%.
This compares to the US$4.5 billion each year (equivalent to 65 cents per person) that the Commission on a Global Health Risk Framework for the Future recommended the world spend on pandemic preparedness in 2016–with most of this investment designated for upgrading public health infrastructure and capabilities in LMICs.
The authors caution that given each country’s reproductive number was fixed for the analysis, the ability of individual-level measures (eg, contact tracing, quarantine, use of cloth masks) to slow transmission of the virus was not taken into account, so the true costs for countries could be lower.
“The costs of a COVID-19 response in the health sector will escalate, particularly if transmission increases”, says Dr Agnès Soucat, Director of the Department of Health Systems Governance and Financing at WHO, Switzerland.
“So instituting early and comprehensive measures to limit the further spread of the virus will be vital if we are to conserve resources and sustain the response.”
“Given the lack of pandemic preparedness in low- and middle-income countries, and the limited resilience of their health systems, major investment will be needed to counter the COVID-19 outbreak–reflecting the constrained health capacity in countries which are facing a virus that has spread and established itself”, says co-author Dr Lucy Boulanger from WHO, Switzerland.
“The arguments for investing in preparedness are strong, juxtaposed against this massive price tag for the response to COVID-19, and coupled with the expected shock on the global economy.”
In February 2020, WHO outlined the priority public health measures required by countries to counter the COVID-19 pandemic in the Strategic Preparedness and Response.
In this study, researchers modelled the future health-care costs of the full response plan to counter the COVID-19 outbreak in 73 LMICs (accounting for 93% of the total population in LMICs) under three scenarios–the status quo in which current measures to restrict movement and ensure physical and social distancing continue so transmission levels are maintained; and under scenarios where restrictions are relaxed and transmission is increased by 50%, or when public health and social measures are intensified and transmission is decreased by 50%.
The number of COVID-19 cases were calculated from June 26, 2020, for each of the three scenarios over four weeks (ie, until July 24) and 12 weeks (until Sept 18), using an SEIR model–which captures the rate that people move from states of being susceptible, to exposed, to infected, and to recovered.
The researchers then modelled the cost of healthcare staff, equipment (eg, personal protective equipment, diagnostic tests), and infrastructure (eg, upgrading laboratories for diagnostic testing, establishing field hospitals to treat COVID-19 patients) that would be accrued by implementing the actions in the strategic response plan.
The total health-care costs for the COVID-19 response in the status quo scenario were estimated at around US$52 billion over four weeks, or US$8?60 per person.
This amounts to around 20% of the health expenditure in low-income countries in 2017 (of US$41 per capita for a whole year).
For the decreased or increased transmission scenarios, the totals were about US$33 billion (US$5.42 per person) and $62 billion (US$10?15 per person), respectively.
Over 12 weeks, the costs are projected to triple under the status quo (US$154 billion) and increased transmission scenarios (US$197 billion), and to reach around US$52 billion in the decreased transmission scenario.
The similarity in the price tag of the status quo scenario for 4 weeks and the decreased transmission scenario for 12 weeks highlights the importance of working to reduce virus transmission and contain the cost of the response, researchers say.
Courtesy: Lancet
Join Daily Trust WhatsApp Community For Quick Access To News and Happenings Around You.
